Hanna Cho1, Jae Yong Choi1, Mi Song Hwang1, Jae Hoon Lee1, You Jin Kim1, Hye Mi Lee1, Chul Hyoung Lyoo2, Young Hoon Ryu1, Myung Sik Lee1. 1. From the Departments of Neurology (H.C., M.S.H., Y.J.K., H.M.L., C.H.L., M.S.L.) and Nuclear Medicine (J.Y.C., J.H.L., Y.H.R.), Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. 2. From the Departments of Neurology (H.C., M.S.H., Y.J.K., H.M.L., C.H.L., M.S.L.) and Nuclear Medicine (J.Y.C., J.H.L., Y.H.R.), Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. lyoochel@yuhs.ac.
Abstract
OBJECTIVE: To investigate the topographical distribution of tau pathology and its effect on functional and structural changes in patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) by using (18)F-AV-1451 PET. METHODS: We included 20 patients with AD, 15 patients with MCI, and 20 healthy controls, and performed neuropsychological function tests, MRI, as well as (18)F-florbetaben (for amyloid) and (18)F-AV-1451 (for tau) PET scans. By using the regional volume-of-interest masks extracted from MRIs, regional binding values of standardized uptake value ratios and volumes were measured. We compared regional binding values among 3 diagnostic groups and identified correlations among the regional binding values, performance in each cognitive function test, and regional atrophy. RESULTS: (18)F-AV-1451 binding was increased only in the entorhinal cortex in patients with MCI, while patients with AD exhibited greater binding in most cortical regions. In the 35 patients with MCI and AD, (18)F-AV-1451 binding in most of the neocortex increased with a worsening of global cognitive function. The visual and verbal memory functions were associated with the extent of (18)F-AV-1451 binding, especially in the medial temporal regions. The (18)F-AV-1451 binding also correlated with the severity of regional atrophy of the cerebral cortex. CONCLUSIONS: Tau PET imaging with (18)F-AV-1451 could serve as an in vivo biomarker for the evaluation of AD-related tau pathology and monitoring disease progression. The accumulation of pathologic tau is more closely related to functional and structural deterioration in the AD spectrum than β-amyloid.
OBJECTIVE: To investigate the topographical distribution of tau pathology and its effect on functional and structural changes in patients with Alzheimer disease (AD) and mild cognitive impairment (MCI) by using (18)F-AV-1451 PET. METHODS: We included 20 patients with AD, 15 patients with MCI, and 20 healthy controls, and performed neuropsychological function tests, MRI, as well as (18)F-florbetaben (for amyloid) and (18)F-AV-1451 (for tau) PET scans. By using the regional volume-of-interest masks extracted from MRIs, regional binding values of standardized uptake value ratios and volumes were measured. We compared regional binding values among 3 diagnostic groups and identified correlations among the regional binding values, performance in each cognitive function test, and regional atrophy. RESULTS: (18)F-AV-1451 binding was increased only in the entorhinal cortex in patients with MCI, while patients with AD exhibited greater binding in most cortical regions. In the 35 patients with MCI and AD, (18)F-AV-1451 binding in most of the neocortex increased with a worsening of global cognitive function. The visual and verbal memory functions were associated with the extent of (18)F-AV-1451 binding, especially in the medial temporal regions. The (18)F-AV-1451 binding also correlated with the severity of regional atrophy of the cerebral cortex. CONCLUSIONS:Tau PET imaging with (18)F-AV-1451 could serve as an in vivo biomarker for the evaluation of AD-related tau pathology and monitoring disease progression. The accumulation of pathologic tau is more closely related to functional and structural deterioration in the AD spectrum than β-amyloid.
Authors: Marta Marquié; Michael Siao Tick Chong; Alejandro Antón-Fernández; Eline E Verwer; Nil Sáez-Calveras; Avery C Meltzer; Prianca Ramanan; Ana C Amaral; Jose Gonzalez; Marc D Normandin; Matthew P Frosch; Teresa Gómez-Isla Journal: Acta Neuropathol Date: 2017-06-13 Impact factor: 17.088
Authors: Davide Bruno; Carey E Gleason; Rebecca L Koscik; Nunzio Pomara; Henrik Zetterberg; Kaj Blennow; Sterling C Johnson Journal: Int J Geriatr Psychiatry Date: 2018-12-10 Impact factor: 3.485
Authors: Young Kyoung Jang; Chul Hyoung Lyoo; Seongbeom Park; Seung Jun Oh; Hanna Cho; Minyoung Oh; Young Hoon Ryu; Jae Yong Choi; Gil D Rabinovici; Hee Jin Kim; Seung Hwan Moon; Hyemin Jang; Jin San Lee; William J Jagust; Duk L Na; Jae Seung Kim; Sang Won Seo Journal: Eur J Nucl Med Mol Imaging Date: 2017-11-16 Impact factor: 9.236
Authors: Sandhitsu R Das; Long Xie; Laura E M Wisse; Ranjit Ittyerah; Nicholas J Tustison; Bradford C Dickerson; Paul A Yushkevich; David A Wolk Journal: Neurobiol Aging Date: 2018-02-09 Impact factor: 4.673
Authors: F Ali; J L Whitwell; P R Martin; M L Senjem; D S Knopman; C R Jack; V J Lowe; R C Petersen; B F Boeve; K A Josephs Journal: J Neurol Date: 2018-03-01 Impact factor: 4.849
Authors: Jennifer L Whitwell; J Eric Ahlskog; Nirubol Tosakulwong; Matthew L Senjem; Anthony J Spychalla; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs Journal: Parkinsonism Relat Disord Date: 2017-12-13 Impact factor: 4.891